Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma, which acquired an 85% royalty interest in Theravance Biopharma Inc.’s asthma/COPD drug Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) for $1.1bn in cash up front and up to $250m in additional payments contingent on the achievement of certain sales milestones anticipated to occur between 2023-2026.
The Trelegy royalties are payable to Theravance from GlaxoSmithKline Pharmaceuticals Ltd. under an alliance initially signed in 2004....